Safety and Compatibility of a New Nourishing Baby Shampoo and Tip to Toe Wash with Stearic Acid

The document detailed a phase 2 clinical trial that assessed the safety and efficacy of SM04554, a topical treatment for male androgenetic alopecia. The trial involved 49 men aged 18-65 with moderate hair loss, who applied either 0.15%, 0.25% SM04554, or a placebo daily for 90 days. Results indicated that the 0.25% dosage significantly increased total follicle counts at Days 91 and 135, with the 0.15% dosage showing similar improvements at Day 135. Increases in various types of hair follicles were observed, particularly in the 0.25% group. While there was no significant change in epidermal ß-catenin and Ki-67, suggesting no proliferative signal, an increase in Ki-67 in the hair bulb was noted, implying hair growth or follicle formation. The study concluded that SM04554 was safe, well-tolerated, and potentially effective in treating male pattern hair loss. The research was funded by Samumed LLC.